CTD Holdings to appoint Dr James E.K. Hildreth to its scientific advisory board
M2 - Tue May 05, 4:34AM CDT
Biotechnology company CTD Holdings (OtherOTC:CTDH) disclosed on Monday the election of Professor James E.K. Hildreth, MD, PhD to its scientific advisory board effective 1 July 2015.
CTD Holdings Names Professor James E.K. Hildreth to Scientific Advisory Board
Marketwire Canada - Mon May 04, 6:17AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced the appointment of Professor James E.K. Hildreth, M.D., Ph.D. to the company's Scientific Advisory Board effective July 1, 2015. Dr. Hildreth was recently named President and Chief Executive Officer of Meharry Medical College, the nation's largest private, independent historically black academic health sciences center.
CTD Holdings Expands International Clinical Program Team
Marketwired - Tue Apr 28, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments and other products, today announced the expansion of its International Clinical Program Team to include Aptus Clinical, Boyd Consultants and KJC Statistics. The clinical research specialists join Accenture in the development of orphan drug Trappsol® Cyclo(TM) for Europe and other markets. Together, Accenture, Aptus, Boyd and KJC bring strong international experience to CTD's orphan drug development program.
Baltimore Sun Publishes Op-Ed by CTD Executive Chairman and Scientific Advisory Board Member
Marketwired - Tue Apr 21, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH) Executive Chairman of the Board N. Scott Fine and Scientific Advisory Board Member Dr. Sharon H. Hrynkow have co-authored a highly insightful and thoughtful op-ed in The Baltimore Sun titled, "Building Local Capacity to Fight Epidemics," which states that the most effective way to stop viruses such as Ebola, MERS and Chikungunya from becoming global pandemics is to prevent them from spreading beyond their point of origin. To do so, local medical virologists in every country must receive training and support that allow them to develop and implement programs that contain and combat viruses.
CTD Holdings awarded orphan drug designation for Trappsol Cyclo in Europe
M2 - Wed Apr 08, 6:54AM CDT
Biotechnology company CTD Holdings (Other OTC:CTDH) reported on Tuesday the receipt of the orphan drug designation for Trappsol Cyclo for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children.
CTD Holdings Obtains European Orphan Drug Designation for Trappsol(R) Cyclo(TM)
Marketwired - Tue Apr 07, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that the European Medicines Agency and European Commission approved transfer of the Orphan Drug Designation for Trappsol® Cyclo(TM) to CTD's European partner, Medical Need Europe (MNE), from Sue and David French and their Niemann Pick Research Foundation. MNE, which is the exclusive distributor of Trappsol® Cyclo(TM) in Europe, will be the official sponsor of the European orphan drug designation on behalf of CTD.
CTD Holdings amends European agreement with Medical Need Europe for new orphan drugs
M2 - Fri Apr 03, 3:07AM CDT
Biotechnology company CTD Holdings (OtherOTC:CTDH) reported on Thursday an amendment in its agreement with Medical Need Europe (MNE) based in Stockholm, Sweden.
CTD Holdings Amends Agreement With Medical Need Europe
Marketwired - Thu Apr 02, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that it has amended its agreement with Medical Need Europe (MNE) such that MNE will be the exclusive distributor in Europe of Trappsol® Cyclo(TM) and any new cyclodextrin-based Orphan Drug Designated treatments that CTD may develop in the future.
CTD Holdings appoints Dr Caroline Hastings to SAB
M2 - Wed Mar 18, 6:40AM CDT
Biotechnology company CTD Holdings (OtherOTC:CTDH) revealed on Tuesday the addition of Caroline Hastings, MD to its Scientific Advisory Board (SAB).
CTD Holdings Names Caroline Hastings, M.D., to Scientific Advisory Board
Marketwired - Tue Mar 17, 6:01AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of Caroline Hastings, M.D., to the company's Scientific Advisory Board. Dr. Hastings joins Dr. Sharon Hrynkow, President of Global Virus Network and Founder and Managing Partner of Global Health Consulting LLC, in advising the Company.
CTD Holdings Selects Accenture to Lead Orphan Drug Clinical Program in Europe
Marketwired - Fri Mar 13, 6:00AM CDT
Accenture (NYSE: ACN) announced today it will provide to CTD Holdings, Inc. (OTCQB: CTDH) data-driven clinical trial strategy and design through its Accelerated R&D Services, a business service that allows pharmaceutical companies to bring drugs to market faster, at less cost and with reduced execution risks. CTD Holdings is a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products.
ACN: 97.02 (+0.04)